Cardiologists may be far more eager to prescribe Eli Lilly's anti-clot drug than expected, a survey finds.

The biotech company's $3 billion purchase of Pharmion makes sound strategic and financial sense.

The price of obesity? Huge. One economist says cash incentives to slim down are the answer.

How did expectations for its promising pill prasugrel get so out of hand?

New data dims outlook for the company's most important experimental drug.